Placental Leucine Aminopeptidase‐  and Aminopeptidase A‐Deficient Mice Offer Insight concerning the Mechanisms Underlying Preterm Labor and Preeclampsia

Mizutani, Shigehiko; Wright, John W.; Kobayashi, Hiroshi

doi:10.1155/2011/286947

Cited by 16 publications

(12 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the pregnant, spontaneously hypertensive rat, APA acts as an antihypertensive agent, degrading vasoactive peptides, and as a result, normalizes blood pressure [58]. The role of aminopeptidases as potential therapeutic agents is being investigated.…”

Section: Novel Therapeutic Targets and Emerging Treatmentsmentioning

confidence: 99%

Drug Treatment of Hypertension in Pregnancy

Brown

Garovic

2014

Drugs

104

View full text Add to dashboard Cite

Hypertensive disorders represent major causes of pregnancy related maternal mortality worldwide. Similar to the non-pregnant population, hypertension is the most common medical disorder encountered during pregnancy and is estimated to occur in about 6–8% of pregnancies [1]. A recent report highlighted hypertensive disorders as one of the major causes of pregnancy-related maternal deaths in the United States, accounting for 579 of the 4693 (12.3%) maternal deaths that occurred between 1998 and 2005 [2]. In low-income and middle-income countries, preeclampsia and its convulsive form, eclampsia, are associated with 10–15% of direct maternal deaths [3]. The optimal timing and choice of therapy for hypertensive pregnancy disorders involves carefully weighing the risk-versus-benefit ratio for each individual patient, with an overall goal of improving maternal and fetal outcomes. In this review we have compared and contrasted the recommendations in different treatment guidelines and we have outlined some newer perspectives on management. We have aimed to provide a clinically orientated guide to the drug treatment of hypertension in pregnancy.

show abstract

Section: Novel Therapeutic Targets and Emerging Treatmentsmentioning

confidence: 99%

Drug Treatment of Hypertension in Pregnancy

Brown

Garovic

2014

Drugs

104

View full text Add to dashboard Cite

show abstract

“…In the pregnant, spontaneously hypertensive rat, APA acts as an antihypertensive agent, degrading vasoactive peptides, and as a result, it normalizes blood pressure [57]. The role of aminopeptidases as potential therapeutic agents is being investigated.…”

Section: Management Of Hypertension In Pregnancymentioning

confidence: 99%

Mechanisms and Management of Hypertension in Pregnant Women

Brown

Garovic

2011

Curr Hypertens Rep

View full text Add to dashboard Cite

Hypertension is the most common medical disorder encountered during pregnancy. A recent report highlighted hypertensive disorders as one of the major causes of pregnancy-related maternal deaths in the United States. Significant advances in our understanding of preeclampsia, a form of hypertension unique to pregnancy, have occurred in recent years. The optimal timing and choice of therapy for hypertensive pregnancy disorders involves carefully weighing the risk-versus-benefit ratio for each individual patient, with an overall goal of improving maternal and fetal outcomes. In this review, we summarize the mechanisms thought to be involved, review the current management guidelines for hypertensive pregnancy disorders as recommended by international guideline groups, and outline some newer perspectives on management.

show abstract

“…P-LAP is mostly synthesized from placental syncytiotrophoblasts during pregnancy. It degrades several peptide hormones which are produced by the fetus such as oxytocin, vasopressin, and angiotensin II [15] Aminopeptidases are large molecules that do not cross the placental barrier; hence they act as antiuterotonic and antihypertensive agents by degrading these peptides [16]. P-LAP activity level in maternal serum increases with the gestational age to reach a maximum near term and reaching a plateau just prior to the onset of labour.…”

Section: Introductionmentioning

confidence: 99%

Utility of Placental Leucine Aminopeptidase/Oxytocinase in the Prediction of Preterm Delivery in Pregnant Women With Threatened Preterm Labor

Hassan

Kadir

Mohammed

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The study objective was to assess the utility of placental leucine aminopeptidase (P-LAP) marker for the prediction of delivery in patients presented with threatened preterm labor (TPL). Setting: This study was conducted at the Obstetrics and Gynaecology Department of Al-Yarmouk Teaching Hospital in the period from March 2017 to June 2018. Type of Study: This is a prospective case control study. Methods: This study included 90 pregnant women with gestational age from (28-36+6) weeks; 45 of them who presented with preterm uterine contractions were considered as the study group which was further subdivided into three subgroups according to gestational age 28–31+6 weeks, 32– 33+6 weeks, and 34–36+6 weeks. The other 45 pregnant women who presented to the hospital for regular antenatal care visit at comparable gestational age to the study group were considered as the control group. Hence, this study aimed to assess the serum level of P-LAP in both groups and compare it between those delivered preterm from term to assess its applicability as a predictor of preterm labor. Results: Serum level of P-LAP in pregnant women presented with TPL was found to be significantly lower in those delivered preterm (p<0.001), compared to those continued to term and control group especially in gestational ages ≥32 weeks, while the study found P-LAP level to be statistically insignificant in gestational age <32 weeks (p=0.052). The cutoff point for P-LAP serum level was = 21 (IU/ml) that below it, the pregnant women with TPL most probably deliver before 37 weeks of gestation with Sensitivity (85.7%) Specificity (90.3%), Positive predictive value (80.0%) Negative predictive (93.3%). Conclusion: The serum level of P-LAP was lower in women delivered preterm than those delivered at term, so it can be used as one of the markers for the prediction of preterm delivery, especially at gestational age >32 weeks.

show abstract

Placental Leucine Aminopeptidase‐ and Aminopeptidase A‐Deficient Mice Offer Insight concerning the Mechanisms Underlying Preterm Labor and Preeclampsia

Cited by 16 publications

References 74 publications

Drug Treatment of Hypertension in Pregnancy

Drug Treatment of Hypertension in Pregnancy

Mechanisms and Management of Hypertension in Pregnant Women

Utility of Placental Leucine Aminopeptidase/Oxytocinase in the Prediction of Preterm Delivery in Pregnant Women With Threatened Preterm Labor

Contact Info

Product

Resources

About